PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Living Drug' trial seeks to fight tough blood cancers
Disease control Recruiting nowThis is an early-stage study to find a safe dose and check the initial safety of a new CAR-T cell therapy called GF-CART01. It is for adults aged 18-70 with certain advanced B-cell blood cancers that have come back or not responded to at least two prior treatments. The therapy in…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 23:11 UTC
-
New hope for patients where CAR-T falls short
Disease control Recruiting nowThis early-stage study is testing a new two-drug combination for patients with B-cell lymphoma. It is for people whose cancer did not respond well enough to a powerful treatment called CAR-T therapy. The goal is to see if adding an oral drug (CC-99282) to an existing antibody dru…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two powerful cancer treatments—CAR-T cell therapy and the drug pembrolizumab—works better than either alone for a type of lymphoma that has returned or not responded to prior treatments. About 35 adults with relapsed or refractory primary m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC